A Ring Or Polycyclo Ring System In A Substituent E Is Attached Indirectly To The Carboxamide Nitrogen Or To An Amino Nitrogen In Substituent E By Acyclic Nonionic Bonding Patents (Class 514/630)
-
Publication number: 20140141100Abstract: Disclosed is a method of treating obesity, reducing weight, preventing weight gain, and/or suppressing appetite in a subject in need thereof by administering topically a pharmaceutical compound having a chemotherapeutic agent to at least a surface of the subject's mouth. The method includes inhibiting taste cell reproduction on the surface of the subject's mouth with the compound and reducing sense of taste, appetite for food in the subject, or a combination thereof.Type: ApplicationFiled: November 20, 2013Publication date: May 22, 2014Inventors: Benedict T. Marino, James F. Marino
-
Patent number: 8729132Abstract: The present invention relates to an agomelatine hydrobromide hydrate of formula I wherein X is Br, preparation and use thereof, and to pharmaceutical compositions containing it. The agomelatine hydrobromide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps.Type: GrantFiled: March 17, 2011Date of Patent: May 20, 2014Assignee: Les Laboratoires ServierInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Patent number: 8729131Abstract: The present invention relates to an agomelatine hydrochloride hydrate of formula I, preparation and use thereof, and to pharmaceutical composition containing it. The agomelatine hydrohalide hydrate obtained through the present method has significant increased solubility than agomelatine, and therefore is more suitable for manufacturing pharmaceutical formulations. In addition, the product enjoys higher stability and purity. Using the present method, product of high purity can be obtained through a simple process, free of any complicated steps. wherein X is Cl.Type: GrantFiled: March 17, 2011Date of Patent: May 20, 2014Assignee: Les Laboratoires ServierInventors: Hanbin Shan, Zhedong Yuan, Xueyan Zhu, Peng Zhang, Hongjuan Pan, Xiong Yu
-
Publication number: 20140135302Abstract: Methods, compositions, and kits for predicting whether a subject with chronic obstructive pulmonary disease (COPD) or at risk of developing COPD is likely to have progressive COPD are provided. Methods, compositions, and kits for predicting whether lung function is likely to decline in a subject with COPD or at risk for developing COPD are also provided.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: SOMALOGIC, INC.Inventors: Malti P. Nikrad, Stuart G. Field, Stephen Alaric Williams, Alex A.E. Stewart, Rachel M. Ostroff, Rosalynn Dianne Gill
-
Patent number: 8722744Abstract: A galenical form for the transmucous administration of at least one active ingredient, characterized in that the active ingredient is paracetamol in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 10% by mass of alcohol so as to allow fast absorption of the active ingredient through the mucous membranes of the buccal cavity and/or the oropharynx. A process for production and the uses of the galenical form are also disclosed.Type: GrantFiled: December 19, 2007Date of Patent: May 13, 2014Inventors: Philippe Perovitch, Marc Maury
-
Publication number: 20140128415Abstract: A excipient drug composition is disclosed. The excipient drug composition may include a vegetable cellulose or a fruit cellulose, an active ingredient and a genetically modified organism free starch. The vegetable cellulose or fruit cellulose may be derived from wood free vegetable pulp and the fruit cellulose is a wood pulp free cellulose. The genetically modified organism free starch may be selected from the group consisting of a genetically modified organism free rice starch, a genetically modified organism free potato starch or a genetically modified organism free pea starch.Type: ApplicationFiled: January 8, 2014Publication date: May 8, 2014Inventor: Paul Daniel Yered
-
Patent number: 8715701Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.Type: GrantFiled: November 20, 2007Date of Patent: May 6, 2014Assignee: Instytut Medycyny Doswiadczalnej I KlinicznejInventors: Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska
-
Patent number: 8716348Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: March 21, 2011Date of Patent: May 6, 2014Assignee: Dey Pharma, L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Patent number: 8710101Abstract: New co-crystal of agomelatine composed of: agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide of formula (I) and an organic acid. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.Type: GrantFiled: June 8, 2012Date of Patent: April 29, 2014Assignee: Les Laboratoires ServierInventors: Philippe Letellier, Michael Lynch, Jean-Manuel Pean
-
Patent number: 8703184Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent.Type: GrantFiled: March 20, 2013Date of Patent: April 22, 2014Assignee: Wellesley Pharmaceuticals, LLCInventor: David A. Dill
-
Publication number: 20140105908Abstract: Disclosed herein are methods and compositions for reducing the recurrence of prostate cancer and for treating prostate cancer.Type: ApplicationFiled: May 3, 2012Publication date: April 17, 2014Applicant: UNIVERSITY OF ROCHESTERInventor: Chawnshang Chang
-
Publication number: 20140094426Abstract: Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolized to a biologically active agent; and X is R, or up to three R moieties attached to a linker, Y1, Y2 or Y3. Self-assembly of the amphiphilic prodrugs into reverse lyotropic phases, particularly hexagonal, cubic and sponge, is disclosed.Type: ApplicationFiled: November 8, 2013Publication date: April 3, 2014Inventors: Calum John Drummond, Sharon Marie Sagnella, Minoo Jalili Moghaddam, Xiaojuan Gong
-
Publication number: 20140088197Abstract: The present invention provides a mixed crystalline form VIII of agomelatine, its method of preparation, application and pharmaceutical composition. The said mixed crystal consists mainly of crystalline form VI of agomelatine. The said mixed crystalline form is stable and has good reproducibility. Through stability tests, it has been found to be superior to the crystalline form VI in terms of stability. As a result, the crystalline form VIII of the present invention possesses advantages in pharmaceutical preparation.Type: ApplicationFiled: March 22, 2012Publication date: March 27, 2014Applicant: LES LABORATORIES SERVIERInventors: Yu Huang, QING Long, Xueyan Zhu, Hanbin Shan, Zhedong Yuan, Xiong Yu
-
Publication number: 20140080800Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: October 28, 2013Publication date: March 20, 2014Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
-
Patent number: 8673982Abstract: This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis.Type: GrantFiled: February 23, 2010Date of Patent: March 18, 2014Assignee: Novartis AGInventors: Volker Brinkmann, Guido Jordine, Markus Zollinger, Claudia Sayer
-
Publication number: 20140065213Abstract: The present invention is directed to twice daily sustained release pharmaceutical composition of paracetamol having an immediate release phase of paracetamol and a sustained release phase of paracetamol, said composition having unique and advantageous pharmacokinetic properties and a pharmaceutical composition comprising only a sustained release phase of paracetamol having unique and advantageous pharmacokinetic properties.Type: ApplicationFiled: May 4, 2012Publication date: March 6, 2014Applicant: GlaxoSmithKline, LLCInventors: Carla Valenti Buan, Dongzhou Liu, Kanji Meghpara
-
Publication number: 20140045946Abstract: A new use for paracetamol in a method of treating glaucoma, which method comprises administering to a patient in need of such treatment 500 mg to 1000 mg of paracetamol in oral format 4 to 6 hourly. An ophthalmic solution is also provided containing between 0.1 to 5% of paracetamol which is administered as one to two drops in each eye 4 to 6 hourly. The ophthalmic solution further includes one or more of the following excipients: hydroxypropylmethylcellulose, benzalconium chloride, polyacrylic acid such as Teargel®.Type: ApplicationFiled: October 2, 2013Publication date: February 13, 2014Applicant: Stellenbosch UniversityInventor: David Meyer
-
Publication number: 20140011883Abstract: The present invention provides a new crystalline form VII of agomelatine, its method of preparation, application and pharmaceutical composition. This new crystalline form offers high purity, a stable crystalline structure and good reproducibility, while its method of production lends itself well to large scale production. In terms of stability and purity, it is superior to the numerous crystalline forms which have hitherto been reported. As a result, the crystalline form VII of the present invention possesses advantages in pharmaceutical preparation.Type: ApplicationFiled: March 22, 2012Publication date: January 9, 2014Applicants: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, LES LABORATOIRES SERVIERInventors: Yu Huang, Ling Tong, Xueyan Zhu, Hanbin Shan, Zhedong Yuan, Xiong Yu
-
Patent number: 8623922Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: December 23, 2011Date of Patent: January 7, 2014Assignee: Dey Pharma, L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Patent number: 8624063Abstract: Compounds which modulate quorum sensing in quorum sensing bacteria. Compounds of the invention inhibit quorum sensing and/or activate quorum sensing in various bacteria. Compounds that inhibit quorum sensing are particularly useful for inhibition of detrimental bacterial biofilm formation. Compounds that activate quorum sensing are particularly useful for promoting growth and biofilm formation of beneficial bacterial.Type: GrantFiled: June 24, 2010Date of Patent: January 7, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Helen E. Blackwell, Christine E. McInnis
-
Publication number: 20130344116Abstract: The present invention relates to compositions and methods of the preparation of an oral particle essentially consisting of an amorphous structure and a submicron domain, wherein both amorphous structure and submicron domain comprise a drug, and wherein the particle shows crystalline property. The desired ratio of the amorphous structure to the submicron domain is between 0.1:5 and 1:1. And, the desired average particle diameter is between mesh 12 (1680 microns) and mesh 100 (149 microns).Type: ApplicationFiled: October 29, 2012Publication date: December 26, 2013Applicant: Magnifica Inc.Inventors: David Wong, James A. Lee, Peter P. Yang
-
Patent number: 8604084Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.Type: GrantFiled: July 29, 2009Date of Patent: December 10, 2013Assignee: GlaxoSmithKline, LLCInventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
-
Publication number: 20130323288Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.Type: ApplicationFiled: June 28, 2013Publication date: December 5, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Publication number: 20130317112Abstract: The present invention relates to a method for the production of a formulation that is stable to oxidation and that is based on paracetamol in an aqueous solvent, comprising the steps of (i) dissolving paracetamol in an aqueous solvent comprising an isotonic agent that is sodium chloride and a buffer agent that is sodium citrate, having a temperature between 65° C. and 95° C. and having pH between 5.0 and 6.0 in a reaction vessel, (ii) replacing the remaining air in the vessel by an inert gas, such as nitrogen, and cooling the solution so formed to a temperature below 38° C., (iii) adding cysteine hydrochloride to the solution without mechanical agitation, and (iv) closing the reaction vessel and mechanically agitating the solution in a nitrogen atmosphere. The further relates to a formulation prepared according to the method.Type: ApplicationFiled: February 10, 2011Publication date: November 28, 2013Applicant: NEOGEN N.V.Inventor: Khaled Al Dandachi Atassi
-
Publication number: 20130295174Abstract: In one aspect, the present invention features a tablet including a first region and a second region, wherein: (i) the first region and the second region each include at least 10%, by volume, of the tablet; (ii) the first region includes a pharmaceutically active agent and the composition of the first region is different from the composition of the second region; (iii) the first region has a density less than about 0.8 g/cc; and (iv) the first region disintegrates in the mouth when placed on the tongue in less than about 30 seconds; wherein the shape of the tablet includes two opposing major faces separated by a side wall, and the interface between the first region and the second region is along at least one major face of the tablet.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: McNeil-PPC, Inc.Inventors: Harry S. Sowden, Gerard P. McNally, Oliver Anderson, William J. Stuhl, Jen-Chi Chen, Kenneth Day, Christopher E. Szymczak
-
Publication number: 20130295175Abstract: The present invention features a tablet containing at least one first material, at least one second material, and at least one pharmaceutically active agent, wherein: (a) the first material is a dielectric water-containing material (i) containing from about 1 to about 5 percent, by weight, of bound water and (ii) having a dielectric loss, when measured at a density of between 0.15 and 0.5 g/cc, of from about 0.05 to about 0.7; and (b) the second material (i) having a water solubility from about 20 to about 400 g per 100 g of water at 25° C., (ii) having a dielectric loss, when measured at a density between 0.5 and 1 g/cc, of less than about 0.05.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: McNeil-PPC, Inc.Inventors: Jen-Chi Chen, Kenneth Day, Christopher E. Szymczak
-
Publication number: 20130289125Abstract: Methods and compositions for pest control, and more particularly for control of ants, e.g., of the subfamily Myrmicinae, using tyramides.Type: ApplicationFiled: November 3, 2011Publication date: October 31, 2013Inventors: Tappey H. Jones, Robert Kenneth Vander Meer
-
Patent number: 8568775Abstract: A medicament tablet containing paracetamol (acetaminophen) as the (or an) active ingredient, and an encapsulated flavorant. The tablet may be swallowed in tablet form or may be dissolved or dispersed in water to form a palatable drink.Type: GrantFiled: April 2, 2007Date of Patent: October 29, 2013Assignee: Reckitt Benckiser Healthcare (UK) LimitedInventor: Paul Frederick Field
-
Patent number: 8552066Abstract: Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an ?,?-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.Type: GrantFiled: May 10, 2010Date of Patent: October 8, 2013Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Rosemarie F. Hartman
-
Publication number: 20130261092Abstract: The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation.Type: ApplicationFiled: May 30, 2013Publication date: October 3, 2013Inventors: Josep BASSAGANYA-RIERA, Amir J. GURI, Raquel HONTECILLAS
-
Publication number: 20130261189Abstract: A pharmaceutical formulation contains 10-60% by weight acetaminophen as the only active ingredient and a solvent system for dissolving the acetaminophen. The formulation is free of any ionizing agent and its solvent system includes water, polyethylene glycol, and polyvinylpyrrolidone that is 2-50% by weight and has a molecular weight of 2,000 to 1,500,000. Also disclosed is another acetaminophen formulation containing polyvinylpyrrolidone as high as 25-50% by weight.Type: ApplicationFiled: March 29, 2012Publication date: October 3, 2013Applicant: Enspire Group LLCInventors: Abdul Rashid, Zhang Julia Zhang, Minh Tran, Dahai Guo
-
Publication number: 20130252890Abstract: The invention relates to selective oestrogen receptor modulators (SERM) and methods of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of bleeding disorders, osteoporosis, endometriosis, myomata, hormone-dependent tumours, for hormone replacement therapy and for contraception.Type: ApplicationFiled: June 21, 2011Publication date: September 26, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Tim Wintermantel, Carsten Möller, Ulrich Bothe, Reinhard Nubbemeyer, Ludwig Zorn, Dirk Kosemund, Antonius Ter Laak, Rolf Bohlmann, Lars Wortmann, Donald Bierer
-
Publication number: 20130244952Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.Type: ApplicationFiled: October 11, 2012Publication date: September 19, 2013Applicant: Abraxis BioScience, LLCInventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
-
Publication number: 20130224291Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.Type: ApplicationFiled: March 20, 2013Publication date: August 29, 2013Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: Wellesley Pharmaceuticals, LLC
-
Patent number: 8518918Abstract: The invention relates to novel combinations based on anticholinergics, ?2-adrenoceptor agonists, PDE 4 Inhibitors, glucocorticoids, and leukotriene-receptor antagonists, process for their production and their use for the treatment of inflammatory diseases, preferably respiratory diseases as bronchial asthma and chronic obstructive pulmonary diseases (COPD) or rheumatic or autoimmune diseases.Type: GrantFiled: September 23, 2011Date of Patent: August 27, 2013Inventors: Joachim Maus, Kastrup Horst, Istvan Szelenyi, Peter Jurgen Cnota, Bauhofer Artur
-
Publication number: 20130217776Abstract: The present invention relates to the use of a combination of agomelatine and a serotonin reuptake inhibitor (SRIs), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.Type: ApplicationFiled: July 19, 2012Publication date: August 22, 2013Applicant: H. Lundbeck A/SInventor: Sandra Willigers
-
Publication number: 20130217777Abstract: The instant invention relates to a process for making inherent low density particles, comprising the steps of (i) providing a powder mixture comprising a swelling agent; (ii) granulating the powder of step (i) with a granulating solution comprising a lipophilic agent into granules and (iii) drying the granules of step (ii). The instant invention further relates to multiparticulate oral gastro-retentive dosage forms comprising the inherent low density particles obtainable by the process.Type: ApplicationFiled: October 20, 2011Publication date: August 22, 2013Applicant: MeliatysInventor: Joel Sylvain Michel Kirkorian
-
Publication number: 20130217656Abstract: The present invention relates to methods, compositions, and diagnostic tests for diagnosing and treating lupus and other related diseases or disease subsets. In particular, the method, compositions, and diagnostic tests relate to a combination of one or more genes, where the expression of these genes indicates a predisposition to develop, or a diagnosis of, lupus and other related diseases or disease subsets.Type: ApplicationFiled: August 12, 2011Publication date: August 22, 2013Applicant: Beth Israel Deaconess Medical Center IncInventor: George C. Tsokos
-
Publication number: 20130210826Abstract: The present invention features methods and compositions for preventing, reducing, or treating a traumatic, metabolic, or toxic peripheral nerve lesion or pain including neuropathic pain, inflammatory, and nociceptive pain by administering to a mammal a compound that reduces expression or activity of BH4. This reduction may be achieved by reducing activity of a BH4 synthetic enzyme, including GTP cyclohydrolase, sepiapterin reductase, or dihydropteridine reductase; antagonizing the cofactor function of BH4 or BH4-dependent enzymes; or blocking BH4 binding to membrane bound receptors. The invention provides methods for diagnosing pain or a peripheral nerve lesion in a mammal by measuring levels of BH4 or its metabolites in biological sample or the levels or activity of any one of the BH4 synthetic enzyme in tissue samples of a mammal.Type: ApplicationFiled: October 11, 2012Publication date: August 15, 2013Applicant: The General Hospital CorporationInventor: The General Hospital Corporation
-
Publication number: 20130202700Abstract: Coated dosage forms comprising a tablet core, preferably in compressed form, that has a coating over its exterior surface and one or more patterns debossed in the tablet surface are disclosed. Methods for manufacturing such dosage forms are also disclosed.Type: ApplicationFiled: February 1, 2013Publication date: August 8, 2013Applicant: MCNEIL-PPC, INC.Inventor: MCNEIL-PPC, INC.
-
Patent number: 8501994Abstract: The compound of formula (I) is a water-stable, long acting ?2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like.Type: GrantFiled: August 22, 2008Date of Patent: August 6, 2013Assignee: Sunovion Pharmaceuticals Inc.Inventors: Craig R. Abolin, H. Scott Wilkinson, Paul McGlynn, William K. McVicar
-
Patent number: 8481060Abstract: The present invention relates to a process for producing a solid, coated pharmaceutical composition by a melt coating process. The process is adapted to provide a solid, coated pharmaceutical composition by melt coating, which has a fast release.Type: GrantFiled: December 17, 2009Date of Patent: July 9, 2013Assignee: Losan Pharma GmbHInventors: Peter Kraahs, Stefanie Bold, Lars Fahsel
-
Patent number: 8476233Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. The subject invention also concerns compositions formulated for oral administration. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered.Type: GrantFiled: June 13, 2008Date of Patent: July 2, 2013Assignee: Therapeutic Research, LLCInventor: Jay Pravda
-
Patent number: 8466144Abstract: The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.Type: GrantFiled: July 18, 2005Date of Patent: June 18, 2013Assignee: Proteosys AGInventor: André Schrattenholz
-
Patent number: 8461211Abstract: The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.Type: GrantFiled: December 30, 2010Date of Patent: June 11, 2013Assignee: AstraZeneca ABInventors: Carl-Axel Bauer, Jan Trofast
-
Publication number: 20130131181Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.Type: ApplicationFiled: November 16, 2012Publication date: May 23, 2013Applicant: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2Inventor: UNIVERSITE VICTOR SEGALEN - BORDEAUX 2
-
Publication number: 20130090355Abstract: The present invention provides methods of preventing or inhibiting tumor metastasis in a subject by administering a therapeutically effective amount of (1) a compound from a group of enumerated compounds, or a pharmaceutically acceptable salt thereof; (2) an agent that covalently modifies at least one cysteine residue of S100A4 protein; or (3) an agent that inhibits the interaction between S100A4 and myosin-IIA.Type: ApplicationFiled: April 28, 2011Publication date: April 11, 2013Applicant: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITYInventor: Anne R. Bresnick
-
Patent number: 8377947Abstract: Use of a composition for treating Alzheimer's disease, osteoporosis, sleep apnea, erectile dysfunction, McArdle disease, or a carbohydrate metabolism disorder, or for reducing aging or fatigue. The composition includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.Type: GrantFiled: March 15, 2010Date of Patent: February 19, 2013Inventor: Chien-Hung Chen
-
Patent number: 8377990Abstract: A novel use of conjugates of psychotropic drugs (e.g., antidepressants or anti-epileptic drugs) and organic acids such as GABA in the treatment of pain is disclosed. A novel GABA conjugate and uses thereof is also disclosed.Type: GrantFiled: July 17, 2007Date of Patent: February 19, 2013Assignees: Ramot at Tel-Aviv University Ltd., Bar-Ilan UniversityInventors: Abraham Nudelman, Ada Rephaeli, Irit Gil-Ad, Abraham Weizman
-
Patent number: RE44874Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseasesType: GrantFiled: December 19, 2012Date of Patent: April 29, 2014Assignee: Glaxo Group LimitedInventors: Philip Charles Box, Diane Mary Coe, Brian Edgar Looker, Panayiotis Alexandrou Procopiou